These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11060721)

  • 21. Targeting complement in therapy.
    Kirschfink M
    Immunol Rev; 2001 Apr; 180():177-89. PubMed ID: 11414360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A blockade of complement activation prevents rapid intestinal ischaemia-reperfusion injury by modulating mucosal mast cell degranulation in rats.
    Kimura T; Andoh A; Fujiyama Y; Saotome T; Bamba T
    Clin Exp Immunol; 1998 Mar; 111(3):484-90. PubMed ID: 9528887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.
    Souza DG; Esser D; Bradford R; Vieira AT; Teixeira MM
    Br J Pharmacol; 2005 Aug; 145(8):1027-34. PubMed ID: 15951831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infusion of routinely stored blood may limit reperfusion injury to acutely ischemic myocardial cells.
    Bagla N; Singh S; Mangal R
    Med Hypotheses; 2005; 64(3):455-7. PubMed ID: 15617847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of complement and perspectives for intervention in transplantation.
    Chen G; Chen S; Chen X
    Immunobiology; 2013 May; 218(5):817-27. PubMed ID: 23182708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion.
    Lauver DA; Lockwood SF; Lucchesi BR
    J Pharmacol Exp Ther; 2005 Aug; 314(2):686-92. PubMed ID: 15872041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for targeting complement inhibitors in ischaemia/reperfusion injury.
    Dong J; Pratt JR; Smith RA; Dodd I; Sacks SH
    Mol Immunol; 1999; 36(13-14):957-63. PubMed ID: 10698350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement therapeutics; history and current progress.
    Morgan BP; Harris CL
    Mol Immunol; 2003 Sep; 40(2-4):159-70. PubMed ID: 12914822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.
    Mizuno M; Morgan BP
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):87-96. PubMed ID: 15032645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ischaemia-reperfusion is an event triggered by immune complexes and complement.
    Chan RK; Ibrahim SI; Verna N; Carroll M; Moore FD; Hechtman HB
    Br J Surg; 2003 Dec; 90(12):1470-8. PubMed ID: 14648724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble complement receptor type I limits damage during revascularization of ischemic myocardium.
    Lazar HL; Hamasaki T; Bao Y; Rivers S; Bernard SA; Shemin RJ
    Ann Thorac Surg; 1998 Apr; 65(4):973-7. PubMed ID: 9564912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement activation following oxidative stress.
    Collard CD; Lekowski R; Jordan JE; Agah A; Stahl GL
    Mol Immunol; 1999; 36(13-14):941-8. PubMed ID: 10698348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C1-esterase inhibitor in ischemia and reperfusion.
    Horstick G
    Immunobiology; 2002 Sep; 205(4-5):552-62. PubMed ID: 12396015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocardial ischaemia and reperfusion injury: reactive oxygen species and the role of neutrophil.
    Saeed SA; Waqar MA; Zubairi AJ; Bhurgri H; Khan A; Gowani SA; Waqar SN; Choudhary MI; Jalil S; Zaidi AH; Ara I
    J Coll Physicians Surg Pak; 2005 Aug; 15(8):507-14. PubMed ID: 16202368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the complement system.
    Marsh JE; Pratt JR; Sacks SH
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):557-62. PubMed ID: 10541217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of increased myocardial ischaemia-reperfusion injury conferred by hypercholesterolaemia through pharmacological inhibition of the caspase-1 cascade.
    Wang TD; Chen WJ; Mau TJ; Lin JW; Lin WW; Lee YT
    Br J Pharmacol; 2003 Jan; 138(2):291-300. PubMed ID: 12540519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement and polymorphonuclear leukocyte activation each play a role in determining myocardial ischemia-reperfusion injury.
    Atsuumi T; Yaoita H; Shichishima T; Maehara K; Fujita T; Maruyama Y
    Jpn Circ J; 2001 Jul; 65(7):659-66. PubMed ID: 11446502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Lectin Pathway of Complement in Myocardial Ischemia/Reperfusion Injury-Review of Its Significance and the Potential Impact of Therapeutic Interference by C1 Esterase Inhibitor.
    Panagiotou A; Trendelenburg M; Osthoff M
    Front Immunol; 2018; 9():1151. PubMed ID: 29910807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of neutrophils in myocardial ischemia-reperfusion injury.
    Jordan JE; Zhao ZQ; Vinten-Johansen J
    Cardiovasc Res; 1999 Sep; 43(4):860-78. PubMed ID: 10615413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
    Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
    Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.